Latest Plasmodium falciparum Stories
Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy.
Interventions targeting malaria, such as insecticide-treated bed nets, antimalarial drugs and mosquito control, could substantially reduce cases of bacteraemia, which kill hundreds of thousands of children each year in Africa and worldwide.
An investigation into the mysterious inner workings of the malaria parasite has revealed that it survives and proliferates in the human bloodstream thanks in part to a single, crucial chemical that the parasite produces internally.
A novel technique to "tame" the malaria parasite, by forcing it to depend on an external supply of a vital chemical, has been developed by researchers at the Stanford University School of Medicine and the University of California-San Francisco.
Scientists at the University of Massachusetts Medical School have uncovered a novel DNA-sensing pathway important to the triggering of an innate immune response for malaria.
Numerous potential anti-malarial candidate drugs have been uncovered by investigators from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Human Genome Research Institute (NHGRI), both parts of the National Institutes of Health (NIH).
Until very recently, it was unclear why infection with malaria causes fever and, under severe circumstances, an infectious death.
Killing over 780,000 people each year, malaria is one of the deadliest diseases in the world.
A cheap, common heartworm medication that is already being used to fight other parasites in Africa could also dramatically interrupt transmission of malaria, potentially providing an inexpensive tool to fight a disease that kills almost 800,000 people each year.